Boston TransTec, LLC is dedicated and positioned to identify, diagnose, and cure diseases. Its flagship product is a novel multifunctional injection catheter (Viper™ Catheter) that has been proven to safely and effectively deliver any kind of therapeutics into the heart, and other organs. This device has been successfully tested on animals in the best US medical centers: Pennsylvania, Columbia, and Harvard Universities. Four letters of intent have been received to purchase the Viper™ immediately upon production; initial annual revenue from these buyers would be over $10 million annually with following exponential increases.

The market potential for a minimally invasive, reliable and effective method for delivering therapeutic agents to the heart muscle and other organs is large. Our product is designed as a minimally invasive catheter-based delivery device to be used with existing treatment modalities, and for new treatments with drug, biopolymers, nanoparticles or gene and stem cell regenerative therapies.

The market for the Viper™ Catheter has developed internationally and is just beginning to develop in the US. The stem cell market has grown from zero in the last three years; analysts at the Stem Cell Summit 2008 forecast its growth to $8.5 billion over the next decade (58% CAGR per year). The Viper™ Catheter will be marketed initially for cardiac applications and the company enjoys an excellent IP position from which derivative catheters and devices can be for other internal organs and associated pathologies.